Cargando…

Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance

Despite unprecedented responses of some cancers to immune checkpoint blockade (ICB) therapies, the application of checkpoint inhibitors in pancreatic cancer has been unsuccessful. Glucocorticoids and glucocorticoid receptor (GR) signaling are long thought to suppress immunity by acting on immune cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Yalan, Xia, Xianghou, Zhao, Yang, Zhao, Zilong, Martinez, Consuelo, Yin, Wenjuan, Yao, Jun, Hang, Qinglei, Wu, Weiche, Zhang, Jie, Yu, Yang, Xia, Weiya, Yao, Fan, Zhao, Di, Sun, Yutong, Ying, Haoqiang, Hung, Mien-Chie, Ma, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649069/ https://www.ncbi.nlm.nih.gov/pubmed/34873175 http://dx.doi.org/10.1038/s41467-021-27349-7

Ejemplares similares

Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis
por: Lau, Poyee, et al.
Publicado: (2022)

STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
por: Hsu, Jung-Mao, et al.
Publicado: (2018)

ZRANB1 is an NBS1 deubiquitinase and a potential target to overcome radioresistance and PARP inhibitor resistance in triple-negative breast cancer
por: Mei, Ying, et al.
Publicado: (2022)

PD-L1-Mediated Gasdermin C Expression Switches Apoptosis to Pyroptosis in Cancer Cells and Facilitates Tumor Necrosis
por: Hou, Junwei, et al.
Publicado: (2020)

An optimized protocol for PD-L1 pathological assessment with patient sample deglycosylation to improve correlation with therapeutic response
por: Wang, Ying-Nai, et al.
Publicado: (2022)

Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I
por: Yamamoto, Keisuke, et al.
Publicado: (2020)

Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation
por: Zhang, Biying, et al.
Publicado: (2023)

Prospects of the potential strategies to improve the efficacy of anti‐PD‐1/PD‐L1 therapy
por: Yamaguchi, Hirohito, et al.
Publicado: (2022)

Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
por: Dhatchinamoorthy, Karthik, et al.
Publicado: (2021)

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
por: Wang, Yiting, et al.
Publicado: (2018)

Dissection of Level III Axillary Lymph Nodes in Breast Cancer
por: Hu, Jiejie, et al.
Publicado: (2021)

Increased Nuclear Transporter KPNA2 Contributes to Tumor Immune Evasion by Enhancing PD-L1 Expression in PDAC
por: Zhou, Kai-Xia, et al.
Publicado: (2021)

The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-Ι
por: Zhang, Yiwen, et al.
Publicado: (2021)

MHC Class I Cross-Presentation by Dendritic Cells Counteracts Viral Immune Evasion
por: Nopora, Katrin, et al.
Publicado: (2012)

TOPK mediates immune evasion of renal cell carcinoma via upregulating the expression of PD-L1
por: Li, Jinxin, et al.
Publicado: (2023)

RIG-I promotes immune evasion of colon cancer by modulating PD-L1 ubiquitination
por: Zhang, Yangyang, et al.
Publicado: (2023)

MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
por: Walter, W, et al.
Publicado: (2000)

Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer
por: Demel, Uta M., et al.
Publicado: (2022)

Editorial: Drug-induced immunogenic cell death patterns and anti-cancer treatment
por: Xia, Xianghou, et al.
Publicado: (2023)

Upregulation of PD‐L1 by SARS‐CoV‐2 promotes immune evasion
por: Huang, Hsiang‐Chi, et al.
Publicado: (2023)

Long noncoding RNA Malat1 inhibits Tead3-Nfatc1–mediated osteoclastogenesis to suppress osteoporosis and bone metastasis
por: Zhao, Yang, et al.
Publicado: (2023)

β-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion
por: Du, Linyong, et al.
Publicado: (2020)

Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
por: Yang, Riyao, et al.
Publicado: (2021)

Development and characterization of anti-galectin-9 antibodies that protect T cells from galectin-9-induced cell death
por: Yang, Riyao, et al.
Publicado: (2022)

Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
por: Ricklefs, Franz L., et al.
Publicado: (2018)

PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy
por: Xu, Yiqi, et al.
Publicado: (2021)

Non-canonical function of DGCR8 in DNA double-strand break repair signaling and tumor radioresistance
por: Hang, Qinglei, et al.
Publicado: (2021)

Chlamydia trachomatis Immune Evasion via Downregulation of MHC Class I Surface Expression Involves Direct and Indirect Mechanisms
por: Ibana, Joyce A., et al.
Publicado: (2011)

An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer
por: Burr, Marian L., et al.
Publicado: (2019)

From Recoding to Peptides for MHC Class I Immune Display: Enriching Viral Expression, Virus Vulnerability and Virus Evasion
por: Atkins, John F., et al.
Publicado: (2021)

Viruses Run: The Evasion Mechanisms of the Antiviral Innate Immunity by Hantavirus
por: Zhang, Yusi, et al.
Publicado: (2021)

Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer
por: Qiu, Yufan, et al.
Publicado: (2021)

Hantavirus-Driven PD-L1/PD-L2 Upregulation: An Imperfect Viral Immune Evasion Mechanism
por: Raftery, Martin J., et al.
Publicado: (2018)

Editorial: Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies
por: Wang, Yiting, et al.
Publicado: (2020)

The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis
por: Wang, Ying-Nai, et al.
Publicado: (2020)

RNF31 represses cell progression and immune evasion via YAP/PD-L1 suppression in triple negative breast Cancer
por: Yang, Huijie, et al.
Publicado: (2022)

Early‐like differentiation status of systemic PD‐1(+) CD8 (+) T cells predicts PD‐1 blockade outcome in non‐small cell lung cancer
por: Khanniche, Asma, et al.
Publicado: (2022)

PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
por: Šmahel, Michal
Publicado: (2017)

Prognostic value of inflammation‐immunity‐nutrition score in patients with hepatocellular carcinoma treated with anti‐PD‐1 therapy
por: Zhang, Zilong, et al.
Publicado: (2022)

Tanshinone IIA promotes vascular normalization and boosts Sorafenib’s anti-hepatoma activity via modulating the PI3K-AKT pathway
por: Qin, Chengdong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jmdgrvul6oth9n3l4m293nff60